慢性粒单核细胞白血病非治愈性治疗结局的回顾性队列研究
该回顾性队列研究纳入38个中心949例接受CMML导向治疗的患者,比较羟基脲、去甲基化药物和强化化疗的结局。调整后分析显示,去甲基化药物总生存优于羟基脲和强化化疗,但在低危患者中未见生存优势。
要点
- 去甲基化药物是高危和骨髓增殖型CMML的首选治疗。
- CPSS有助于识别最可能从去甲基化药物获益的患者。
- 低危CMML患者接受去甲基化药物未见总生存优势。
核心结论
- 数据提示去甲基化药物是高危CMML和骨髓增殖型CMML患者的首选治疗。
- CPSS是识别最可能从去甲基化药物获益患者的有价值工具。
- 低危患者(MDS型CMML且原始细胞<10%、CMML-0或低危CPSS)接受去甲基化药物未获总生存优势。
研究设计与样本
- 回顾性队列研究,数据于2017年11月30日至2019年1月5日取自美国和欧洲38个中心。
- 纳入非选择性、连续诊断的CMML并接受CMML导向治疗的患者,排除初诊符合2016 WHO急性髓系白血病标准或治疗数据不可用者。
- 共纳入1981年4月13日至2018年10月26日诊断的949例患者,按首次治疗分为羟基脲、去甲基化药物和强化化疗组。
- 分析按年龄、性别、血小板计数和CPSS校正。
主要发现
- 412例(43%)首选去甲基化药物,391例(41%)羟基脲,83例(9%)强化化疗。
关键数值与推荐
- 去甲基化药物作为首选治疗者占43%(412/949)。
- 羟基脲作为首选治疗者占41%(391/949)。
- 强化化疗作为首选治疗者占9%(83/949)。
- 低危定义:MDS型CMML且原始细胞<10%、CMML-0或低危CPSS。
临床怎么用
- 高危CMML及骨髓增殖型CMML可优先考虑去甲基化药物。
- 可用CPSS评估患者从去甲基化药物获益的可能性。
- 低危CMML选择去甲基化药物前应权衡其缺乏生存优势的证据。
局限性
- 为回顾性队列研究,作者建议需以前瞻性队列进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approval of hypomethylating agents in patients with chronic myelomonocytic leukaemia is based on trials done in patients with myelodysplastic syndromes. We aimed to investigate whether hypomethylating agents provide a benefit in subgroups of patients with chronic myelomonocytic leukaemia compared with other treatments. METHODS: For this retrospective cohort study, data were retrieved between Nov 30, 2017, and Jan 5, 2019, from 38 centres in the USA and Europe. We included non-selected, consecutive patients diagnosed with chronic myelomonocytic leukaemia, who received chronic myelomonocytic leukaemia-directed therapy. Patients with acute myeloid leukaemia according to 2016 WHO criteria at initial diagnosis (ie, ≥20% blasts in the bone marrow or peripheral blood) or with unavailability of treatment data were excluded. Outcomes assessed included overall survival, time to next treatment, and time to transformation to acute myeloid leukaemia. Analyses were adjusted by age, sex, platelet count, and Chronic myelomonocytic leukaemia-Specific Prognostic Scoring System (CPSS). Patients were grouped by first received treatment with either hydroxyurea, hypomethylating agents, or intensive chemotherapy, and stratified by risk according to blast count, French-American-British subtype, CPSS, WHO 2016 subtype, and the eligibility criteria of the DACOTA trial (NCT02214407). FINDINGS: 949 patients diagnosed with chronic myelomonocytic leukaemia between April 13, 1981, and Oct 26, 2018, were included. Median follow-up was 23·4 months (IQR 11·5-42·3) from diagnosis and 16·2 months (6·6-31·6) from start of first-line treatment. 412 (43%) of 949 patients received hypomethylating agents as first treatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy. Adjusted median overall survival for patients treated with hydroxyurea versus hypomethylating agents was 15·6 months (95% CI 13·1-17·3) versus 20·7 months (17·9-23·4); hazard ratio (HR) 1·39 (1·17-1·65; p=0·0002) and 14·0 months (9·8-17·2) versus 20·7 months (17·9-23·4; HR 1·55 [1·16-2·05]; p=0·0027) for those treated with intensive chemotherapy versus hypomethylating agents. In patients with myeloproliferative chronic myelomonocytic leukaemia (myeloproliferative CMML), median overall survival was 12·6 months (10·7-15·0) versus 17·6 months (14·8-21·5; HR 1·38 [1·12-1·70]; p=0·0027) for patients treated with hydroxyurea versus hypomethylating agents, and 12·3 months (8·4-16·6) versus 17·6 months (14·8-21·5; HR 1·44 [1·02-2·03]; p=0·040) for intensive chemotherapy versus hypomethylating agents. Hypomethylating agents did not confer an overall survival advantage for patients classified as having lower-risk disease (ie, myelodysplastic chronic myelomonocytic leukaemia with <10% blasts, CMML-0, or lower-risk CPSS). INTERPRETATION: These data suggest hypomethylating agents as the preferred therapy for patients with higher-risk chronic myelomonocytic leukaemia and those with myeloproliferative CMML. Our findings also suggest that CPSS is a valuable tool to identify patients who are most likely to benefit from hypomethylating agents. Further evidence from prospective cohorts would be desirable. FUNDING: The Austrian Group for Medical Tumor Therapy.
引用
- Pleyer L, Leisch M, Kourakli A, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021. PMID: 33513373. doi:10.1016/S2352-3026(20)30374-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。